Resource Logo
NLM AIDSLINE

Natural history of AIDS in a cohort of hemophiliacs.




 

Int Conf AIDS. 1993 Jun 6-11;9(1):280 (abstract no. PO-B01-0872). Unique

OBJECTIVE/METHODS: To update the natural history of AIDS in a cohort of HIV(+) hemophiliacs (n = 84) on whom HIV seroconversion dates are known, we compared CD4 and Kaplan Meier estimates for cumulative AIDS risk, by age and by antiretroviral (AZT) treatment, (RX) (n = 40) vs. no treatment (NoRX) (n = 44). RESULTS: A total of 43 (52.1%) have progressed to AIDS with mean CD4 52/mm3 (median 39/mm3) at dx. The overall cumulative AIDS risk at 5, 7.5, and 11 year after SC is 18%, 32%, and 49%: for RX, 2.5%, 12.5%, and 30%, and for NoRX, 32%, 61%, and 65%, respectively. Median CD4 at AIDS dx for those < or = 18, 19-30, > 30 yr at SC was 12/mm3, 29mm3, and 54/mm3. Mean CD4 at dx was 30 8/mm3 for RX vs. 63 +/- 13/mm3 for NoRX, p < .01. Median CD4 response 6 and 12 months after AZT was +31/mm3 and -37/mm3 for asymptomatic (baseline 330/mm3), and -34/mm3 and -49/mm3 for AIDS/ARC (baseline 66/mm3), respectively. CONCLUSION: One-half of this cohort has developed AIDS at 11 years after SC: although CD4 response to antiviral treatment is poor, time to AIDS is longer and CD4 number lower at AIDS dx in those treated with AZT, and in those younger at SC.

*Acquired Immunodeficiency Syndrome/COMPLICATIONS *Hemophilia/COMPLICATIONS



 




Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.